In the November 2022 U.S. midterm elections, Democrats will be decisively defeated in a Republican landslide if they continue to focus their messaging on January 6th rather than voter-priority issues like inflation, the economy, COVID, crime, and schools.
“If you and the Democrats keep talking about this and focus on it on MSNBC to the exclusion of the issues that really matter. I'll see you in November because you're going to get slaughtered in this midterm election. It's going to be a landslide.”
View on YouTube
Explanation
The November 2022 midterms produced only a modest Republican House majority, not the decisive landslide 'slaughter' predicted.
The November 2022 U.S. midterm elections will feature a large Republican "red wave," and the magnitude of GOP gains will increase if Democrats continue to focus heavily on January 6th instead of bread-and-butter issues.
“If you want to focus on that, to the exclusion of the real issues facing the country, like I said, this landslide in November, this red wave is going to be even bigger.”
View on YouTube
Explanation
The predicted 'red wave' in November 2022 was smaller than expected, not larger.
Over the roughly ten months following this January 2022 recording, if Democrats and MSNBC continue to emphasize January 6th coverage, the Republican "red wave" in the November 2022 midterm elections will be especially large.
“If you watch MSNBC, it's all January 6th all the time. And, you know, if Democrats are going to focus on this issue for the next ten months... This red wave in November is going to be an even bigger wave.”
View on YouTube
Explanation
The November 2022 red wave was notably underwhelming compared to expectations, not bigger.
If President Biden had prioritized it, a reform/clarification of the U.S. Electoral Count Act could have passed the Senate in this Congress (2021–2023) with at least 60 votes, i.e., with significant bipartisan support.
“Biden could have gotten 60 votes for that. You know, I think that was very doable.”
View on YouTube
Explanation
Electoral Count Act reform did pass Congress with substantial bipartisan support, included in the December 2022 omnibus spending bill.
Legislation to ban or severely restrict insider trading by members of the U.S. Congress would be able to obtain a huge bipartisan majority in the current Congress (2021–2023), meaning support from large numbers of both Republicans and Democrats, if it were brought forward.
“Pelosi. But but but but yeah, I think it is something that would get a huge bipartisan majority.”
View on YouTube
Explanation
A comprehensive congressional insider trading ban did not pass during that Congress despite bipartisan interest.
Nancy Pelosi will lose her position of power after the 2022 elections (implicitly, Democrats will lose the House majority in November 2022 and she will cease to be Speaker), so President Biden can politically afford to oppose her on issues like an insider trading ban.
“Look, she's going to lose anyway. So he might as well just throw under the bus.”
View on YouTube
Explanation
Democrats lost their House majority in the November 2022 elections and Pelosi stepped down from House Democratic leadership afterward.
In the years following January 6, 2021, U.S. federal law-enforcement and security agencies will use public and political hysteria about the Capitol riot to justify and obtain expanded powers of surveillance and authority over American citizens.
“you should understand that the hysteria created around that event is going to be used. It's going to be exploited to demand these powers.”
View on YouTube
Explanation
Debate over expanded surveillance powers tied to January 6th did occur, but no single major new law is clearly attributable to exploiting 'hysteria' from the event in the way predicted.
Following this Epstein–Barr virus (EBV)–MS paper (published January 2022), new clinical trials will be initiated in the near term to test EBV-targeted therapies, including T‑cell therapies, in multiple sclerosis patients to see if clearing or suppressing EBV reduces or eliminates the need for ongoing MS treatments.
“So that's the clinical trials that will start now. Because if you can give people a T cell therapy and eliminate EBV and stop all future need for Ms. treatment, that'll save 40 grand a year, it'll start to make sense to run clinical studies to see if that stuff's possible and is worth doing.”
View on YouTube
Explanation
Clinical research into EBV-targeted therapies for multiple sclerosis, including T-cell approaches, has advanced significantly in the years following this January 2022 paper.
The strong epidemiological data in the January 2022 Epstein–Barr virus–MS paper will trigger a noticeable increase in investment (public, private, or both) into EBV-related therapeutics and vaccines over the subsequent few years.
“By the way, this isn't novel. People have been talking about this for a long time, but this paper has such incredible data and such strong signal that it's really gonna it's really going to catalyze investment.”
View on YouTube
Explanation
The EBV-MS link paper catalyzed substantially increased research and investment interest in EBV-related therapeutics in subsequent years.